In follicular lymphoma, Hb of <12 g/dL was known to be prognostic [9,10], but Chen et al. [11] showed that Hb of <12 g/dL did not show a significant association with inferior PFS or OS in DLBCL patients treated with rituximab-containing immunochemotherapy. This evidence concerns the gene GSTM1 and follicular lymphoma.